Liquidia Corporation
LQDA
Kedudukan dalam Saham
#4844
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating... Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Harga Saham
$34.12
Disegerakkan terakhir: 2026-10-19
Modal Pasaran
$3.05B
Perubahan (1 hari)
-0.67%
Perubahan (1 tahun)
39.61%
Negara
US
Perdagangan Liquidia Corporation (LQDA)
Kategori
Healthcare
Nisbah P/S bagi Liquidia Corporation (LQDA)
Nisbah P/S pada October 2026 TTM: 6.74
Menurut laporan kewangan dan harga saham terkini Liquidia Corporation, nisbah P/S semasa (TTM) ialah 6.74. Pada akhir 2023, nisbah P/S syarikat ialah 44.71.
Sejarah nisbah P/S untuk Liquidia Corporation dari 2016 hingga 2026
Nisbah P/S pada akhir setiap tahun
| Tahun | Nisbah P/S | Ubah |
|---|---|---|
| 2026 (TTM) | 6.74 | -89.81% |
| 2024 | 66.13 | 47.92% |
| 2023 | 44.71 | 83.47% |
| 2022 | 24.37 | 29.46% |
| 2021 | 18.82 | -86.07% |
| 2020 | 135.16 | 1,280.87% |
| 2019 | 9.79 | -82.92% |
| 2018 | 57.32 | 336.47% |
| 2017 | 13.13 | 82.10% |
| 2016 | 7.21 | 0.00% |
Nisbah P/S untuk syarikat atau pesaing yang serupa
| Syarikat | Nisbah P/S | Perbezaan Nisbah P/S | Negara |
|---|---|---|---|
| 10.31 | 53.04% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 2.36 | -64.97% |
HK
|
